» Articles » PMID: 31542837

Clinical and Pathological Features of Immunoglobulin A Nephropathy Patients with Nephrotic Syndrome

Overview
Journal Clin Exp Med
Specialty General Medicine
Date 2019 Sep 23
PMID 31542837
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

IgA nephropathy (IgAN) is the most common glomerulonephritis worldwide. The classic manifestation of IgAN is episodic hematuria and proteinuria. Nephrotic syndrome (NS) is not very common in IgAN, reported to occur in only 5-10% of IgAN patients. However, the clinical and pathological characteristics and long-term outcomes of patients with NS-IgAN at onset remain unknown. A retrospective study was conducted, enrolling 1165 patients with biopsy-proven IgAN from West China Hospital in 2008-2015. Patients with renal biopsy of minimal change disease with mesangial IgA deposits were excluded. The renal endpoint was defined as 50% decrease in eGFR or progressing into end-stage renal disease (ESRD). A total of 1165 patients were enrolled with average age of 34.58, and 171 (14.7%) patients were presented with NS. Comparing NS and non-NS groups, significance differences were shown in hypertension (HTN), 24-h urine protein, serum albumin, serum creatine, eGFR and uric acid. NS group had severe pathological changes such as endocapillary hypercellularity, tubular atrophy or interstitial fibrosis and crescent, but less segmental glomerulosclerosis or adhesion and global sclerosis. During the average follow-up of 44.27 months, 29.8% (51/171) NS patients and 15.8% (157/994) non-NS patients progressed to the renal endpoint. 5-year renal survival rates were 73.1% and 87.8% (P < 0.001) in NS and non-NS groups, respectively. This study demonstrated that IgAN patients with NS had higher serum creatine, lower eGFR, lower uric acid, more acute lesions and poor prognosis. NS was an independent risk factor for progression to the renal endpoint.

Citing Articles

The Outcomes of IgA Nephropathy With Nephrotic Syndrome: A Clinicopathological Study From Northern India.

Abdullah , Pushkar D, Kaul A, Behera M, Khurana M, Prasad N Cureus. 2025; 16(12):e76307.

PMID: 39867081 PMC: 11761544. DOI: 10.7759/cureus.76307.


Clinical features, pathological characteristics, and prognosis of patients with IgA nephropathy complicated with nephrotic syndrome.

Tan L, Jin L, Wang Y, Chen W, Wen Q Sci Rep. 2025; 15(1):1804.

PMID: 39805984 PMC: 11729869. DOI: 10.1038/s41598-025-86081-0.


Efficacy and safety of rituximab in primary IgA nephropathy: a retrospective study.

Li J, Nie Z, Li G, Bao B Clin Exp Nephrol. 2024; .

PMID: 39729155 DOI: 10.1007/s10157-024-02617-0.


The Latest Progress in the Application of Telitacicept in Autoimmune Diseases.

Liu B, Zhao Y, Liu D, Li X, Ma Z, Yang Q Drug Des Devel Ther. 2024; 18():5811-5825.

PMID: 39664967 PMC: 11633291. DOI: 10.2147/DDDT.S493923.


Contemporary review of IgA nephropathy.

Filippone E, Gulati R, Farber J Front Immunol. 2024; 15:1436923.

PMID: 39188719 PMC: 11345586. DOI: 10.3389/fimmu.2024.1436923.


References
1.
Li X, Liang S, Le W, Cheng S, Zeng C, Wang J . Long-term outcome of IgA nephropathy with minimal change disease: a comparison between patients with and without minimal change disease. J Nephrol. 2015; 29(4):567-73. DOI: 10.1007/s40620-015-0242-9. View

2.
Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

3.
Zhang L, Li J, Yang S, Huang N, Zhou Q, Yang Q . Clinicopathological features and risk factors analysis of IgA nephropathy associated with acute kidney injury. Ren Fail. 2016; 38(5):799-805. DOI: 10.3109/0886022X.2016.1163153. View

4.
Donadio J, Bergstralh E, Grande J, Rademcher D . Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy. Nephrol Dial Transplant. 2002; 17(7):1197-203. DOI: 10.1093/ndt/17.7.1197. View

5.
Lai K, Lai F, Ho C, Chan K . Corticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial. Clin Nephrol. 1986; 26(4):174-80. View